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The molecular background of variant forms of GYPB is not well 
studied in Brazilians of African descent.  The present study was 
carried out to determine the molecular bases of the S–s– phe-
notype and the frequency of GYPB*S silent gene for the S–s+ 
phenotype in a blood donor population of African Brazilians. 
In this study, 165 blood samples from African Brazilians 
(Northeastern Brazil) who phenotyped as S–s– (n = 17) and S–s+ 
(n = 148) by hemagglutination were selected.  Allele-specific 
(AS)-PCR and PCR-restriction fragment length polymorphism 
(RFLP) were used to identify the variant forms of GYPB.  In 13 
of 17 S–s– samples (76.5%), both GYPB were deleted.  In 137 of 
the 148 S–s+ samples (92.6%), the AS-PCR was consistent with 
the S–s+ phenotype.  In 4 of the S–s– samples (23.5%) and 11 
of the S–s+ samples (7.4%), the AS-PCR showed the presence 
of a GYPB*S allele associated with silencing of S.  In the 4 
donors with the S–s– phenotype, there was homozygosity (or 
hemizygosity) for the GYP(P2) allele (n = 2), homozygosity (or 
hemizygosity) for the GYP(NY) allele (n = 1), and heterozygosity 
for the GYP(P2) and GYP(NY) alleles (n = 1).  In the 11 donors 
with the S–s+ phenotype, there was heterozygosity for GYP(P2) 
allele (n = 8) and heterozygosity for GYP(NY) allele (n = 3). 
This study reports for the first time the molecular mechanisms 
responsible for the S–s– phenotype in a population of African 
Brazilians and provides new information about the frequency 
and molecular bases of the GYPB*S silent gene (7.4%) in this 
population.  Immunohematology 2008;24:148-153.
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The MNS blood group system is a highly complex 
system that consists of more than 40 distinct anti-
gens.1  These antigens are carried on glycophorin A 
(GPA), glycophorin B (GPB), or hybrid proteins that 
arise from unequal crossover, nucleotide substitution, 
or gene conversion events between the glycophorin 
genes.2
The genes encoding GPA (GYPA) and GPB 
(GYPB) are located on chromosome 4 together with 
a third gene of this glycophorin family, GYPE.  In ad-
dition to sequence homology and proximity between 
the glycophorin genes, recombination hot spots 
have been identified and demonstrated to generate 
many different hybrid GYP gene products at the RBC 
surface, as a result of reciprocal and nonreciprocal 
exchange of nucleic acids.3  These hybrid molecules 
often carry one or more novel antigens of the MNS 
blood group system.  Furthermore, the expression of 
more common MNS system antigens, such as S or s, 
may be affected if the encoding sequence is close to 
the crossover site, manifested by unexpected results 
with some antisera.4  In addition, Storry et al.,5 study-
ing the molecular bases of the weakened expression 
of S or s associated with the low-incidence antigens 
Mv, sD, and Mit, showed that Arg35 is important for 
full expression of S and Pro39 and Thr3 were also 
important for full expression of s.
The absence of GPB on the RBCs as a result 
of a GYPB gene deletion is characterized by the 
S–s– phenotype,6 which is found in persons of 
African descent.  RBCs of approximately 1 percent 
of African Americans, and up to 37 percent of West 
Africans, type as S–s–.  The S–s– phenotype is asso-
ciated either with the absence of the high-prevalence 
antigen, U, or with weakened expression of U (U+var). 
U is commonly found in all populations.  The S–s–U– 
phenotype is found among Black ethnic groups and 
appears to correlate with the geographic prevalence 
of malaria infection as a result of the deletion of 
GYPB, whereas the S–s–U+var phenotype has been 
associated with two variant GPB proteins.7–9
Storry et al.4 reported in 2003 a large cohort study 
of S–s– donors to determine the molecular alterations 
of the S–s– phenotype and their distribution in the 
African American population.  In this study, it was 
confirmed that DNA from donors whose RBCs failed 
to react with a potent anti-U/GPB was not amplified 
by allele-specific or gene-specific primers designed 
to detect GYPB.  In contrast, donors whose RBCs 
were reactive with anti-U/GPB demonstrated the 
presence of variant forms of GYP.He (in the major-
ity of samples) or of GYPB by allele-specific assays. 
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The GYP.He variant is an altered form of GPB (B-A-B 
hybrid gene) as a result of a gene recombinational 
event.  The ultimate result of this event was the 
generation of a composite sequence defining the 
Henshaw (He) epitope with a concomitant abolition 
of the GPB-associated “N” antigen in some Africans.7 
All these samples demonstrated the presence of the 
silenced GYPB*S allele.  The absence of S at the RBC 
surface was demonstrated to be caused by a change 
at nucleotide 208 (G>T) and 230 (C>T) of exon 5 
(named variant GYPB[NY], or GYPHe[NY]), or a g>t 
change at +5 of intron 5 (named variant GYPB[P2], 
or GYPHe[P2]), which led to partial or complete exon 
skipping.  Sequencing and PCR-restriction fragment 
length polymorphism (RFLP) analyses showed that 
the GYP(P2) allele was the most common mechanism 
in donors and patients with the S–s–U+var phenotype. 
The N-terminus of glycophorins carrying either 
GP(P2) or GP(NY) can express “N” or He antigens.4
In this study, DNA-based assays were used to 
identify variant forms of GYPB in Brazilian blood 
donors of African descent with the S–s– and S–s+ 
phenotypes.  GYP(P2) and GYP(NY) alleles have 
been identified as the mechanisms for the S–s–U+var 
and have also explained the presence of the GYPB*S 




EDTA blood samples were obtained from healthy 
volunteer blood donors, who self-identified their eth-
nicity as African Brazilians, at the Sao Rafael Hospital 
Blood Bank.  Institutional Review Board–approved 
informed consent was obtained from each blood 
donor.
Serologic Analysis
The S/s/U status of donors’ RBCs was determined 
by IAT-hemagglutination in gel cards (DiaMed AG, 
Morat, Switzerland) using commercially available 
polyclonal anti-S and anti-s (Immucor, Norcross, GA) 
and single-source plasma or serum samples from 
donors or patients (human polyclonal anti-U).  After 
the determination of the antigen profile, aliquots 
of 200 µL of 17 S–s–U– and 148 S–s+ samples were 
subjected to DNA analysis.
Genomic DNA Extraction
Genomic DNA was isolated by a whole-blood 
DNA extraction kit (Easy DNA, Invitrogen, Carlsbad, 
CA) according to the manufacturer’s instructions. 
The DNA solutions were analyzed for quality by aga-
rose gel electrophoresis.  Quantification tests were 
not performed after extraction by this procedure; 
however, the expected yield was 3 to 12 µg of DNA.
Allele-Specific PCR
Allele-specific PCR (AS-PCR) for the S/s alleles 
were performed in all 17 S–s–U– and 148 S–s+ 
samples to characterize the alleles present.  The 
sequences of primer combinations and control prim-
ers that amplified an unrelated gene (human growth 
hormone gene) were previously published.4  AS-PCR 
was carried out under the following conditions: 1× 
PCR buffer, 1.5 mmol/L MgCl2, 0.2 mmol/L dNTP 
mix, 100 ng of sense and antisense primers, 100 ng 
of control primers, and 2.5 U Taq DNA polymerase. 
Two microliters of genomic DNA was used per 50-µL 
assay.  Amplification was performed using a standard 
35-cycle protocol, with an annealing temperature of 
62°C.
GYPB Exon 5 Combination AS/PCR-RFLP Assay
Genomic DNA samples from the 4 nondeletion 
type S–s–U+var samples and 11 S–s+ samples were 
amplified with the GPB4/5, GPBIVS5, and GPB5T 
primers, using a combination AS/PCR-RFLP assay4 to 
determine whether GYPB is present or absent and 
to distinguish the variant GYPB gene products in 
nondeletion type S–s– and S–s+ (GYPB*S silent gene) 
donors.  The PCR products were digested with EcoRI 
(MBI, Fermentas, Amherst, NY) during an overnight 
incubation at 37°C.  The uncut and digested products 
were analyzed on a 10% polyacrylamide gel.
Results
Serologic Analysis
RBCs from 165 blood samples were initially tested 
with polyclonal anti-S and anti-s by IAT-hemaggluti-
nation in gel test cards to determine the S/s profile. 
Of these, 17 samples were phenotyped as S–s– and 
148 were S–s+.  None of the S–s– samples reacted 
with our human polyclonal anti-U (n = 17) and were 
serologically classified as S–s–U–.
Allele-Specific PCR
Genomic DNA from the 165 samples was analyzed 
by AS-PCR assay for GYPB*S/s.  The GYPB*S-specific 
primer pair amplified products in 4 of the 17 S–s– and 
11 of the 148 S–s+ samples (Table 1).  No amplification 
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was obtained in the other 13 S–s– samples, indicating 
that GYPB was deleted in these samples.  The remain-
ing 137 S–s+ samples only gave amplified products 
with the GYPB*s-specific primer, suggesting homozy-
gosity or hemizygosity for GYPB (Fig. 1).
GYPB Exon 5 Combination AS/PCR-RFLP Assay
Genomic DNA from the 4 S–s– and 11 S–s+ 
samples that gave amplified products for GYPB*S-
specific primer were analyzed by the GYPB exon 5 
combination AS/PCR-RFLP assay, and the results are 
summarized in Tables 2 and 3, respectively.  This 
combination assay was validated by Storry et al.4 to 
determine whether GYPB is present or absent and, 
if GYPB is amplified, whether it is the GP(P2) or the 
GP(NY) form (Fig. 2).
The digested products from the four S–s– samples 
showed the following patterns: two were homozy-
gous (or hemizygous) for the nucleotide change at 
+5 (g>t) of intron 5, consistent with variant GYP(P2), 
one was homozygous (or hemizygous) for nucleotide 
changes at nt208 (G>T) and nt230 (C>T), consistent 
with variant GYP(NY), and one was a heterozygous 
variant form for both GYP(NY)/GYP(P2) alleles.
In the 11 samples that phenotyped as S–s+, we 
found the following electrophoresis profile in the 
digested products: 8 had a nucleotide change at +5 
(g>t) of intron 5, consistent with variant GYP(P2), and 
3 presented with changes at nt208 and nt230, consis-
tent with variant GYP(NY).  The African Brazilians’ 
samples phenotyped as S–s+ were included in this 
study to extend the molecular characterization of 
variant GYPB.  They provided evidence of a high 
prevalence (7.4%) of GYPB*S in this population.  In 
samples that were apparently homozygous for the 
GYPB*s allele, it is not possible to determine whether 
the partner chromosome has a deleted GYPB.
Discussion
In the present study, the molecular background 
of variant forms of GYPB in Brazilian blood donors 
of African descent was determined for the first time 
through analyses of S–s– and S–s+ phenotypes.  This 
is particularly important because the ability to detect 
these variant forms within a population of patients 
with sickle cell disease (SCD) or other hemoglobin-
opathies and of Black donors ensures the best match 
and transfusion safety.  Moreover, the GYPB exon 5 
combination assay is useful to readily identify GYPB-
deleted donors for those patients whose antibody is 
compatible only with GYPB-deleted RBCs and also 
permits the identification of the silent S allele to 
resolve the discrepancies between hemagglutina-
tion and DNA-based assays.  Clinical issues must be 
addressed for S–s–U– patients or for those who are 
S–s–U+var; as shown by Storry et al.,4 they can produce 
anti-U when exposed to antigen-positive RBCs.  This 
premise is consistent with other reports of clinically 
significant transfusion reactions in SCD patients10 and 
several cases of hemolytic disease of the fetus and 
newborn11–13 caused by anti-U.  Transfusion of alloim-
munized patients requiring S–s–U– RBC components 
is a challenge for any transfusion service because 
of the lack of well-characterized serologic screen-
ing reagents.  PEG-IAT and MTS-gel with broadly 
reactive anti-U/GPB are the methods of choice to 
detect S–s–U+var.14 However, current knowledge of 
the molecular bases associated with expression of 
variant antigens makes DNA testing an important 
tool for both screening donors and typing patients. 
Therefore, it is now feasible to genotype donors to 
identify S–s–U– phenotypes.
In 1987, Huang et al.6 reported two unrelated 
individuals who exhibited the S–s–U– phenotype 
lacking GPB and observed that the absence of this 
protein correlated with deletion of GYPB.  Gene 
deletion is a common mechanism for some human 
genetic disorders, most notably thalassemias.15 
Table 1. Results of AS-PCR for GYPB*S/s
   GYPB*S	 No GYPB*S 
 Serologic  amplified amplified 
 results Number product product
 S–s–U– 17 4 13*
 S–s+ 148 11 137
*No GYPB*S or GYPB*s amplified products.
Table 2. Results of testing 17 S–s– DNA samples by AS/PCR-RFLP 
assay
 Number Variant gene Type of nucleotide change
 2 GYP(P2) +5 intron 5(g>t)
 1 GYP(NY) nt208 (G>T) and nt230 (C>T)
 1 GYP(NY)/GYP(P2)  nt208 (G>T) and nt230 
(C>T)/+5 intron 5 (g>t)
 13 GYPB deletion –
Table 3. Results of testing 11 S–s+ DNA samples by AS/PCR-RFLP 
assay
 Number Variant gene Type of nucleotide change
 8 GYP(P2) +5 intron 5(g>t)
 3 GYP(NY) nt208 (G>T) and nt230 (C>T)
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Certain thalassemias occur in geographically de-
fined groups of individuals, for which it has been 
presumed that the absence of the α or β globin gene 
may have represented a selective advantage.  It is 
therefore of interest that the S–s–U– phenotype is 
prevalent among selected populations, in particular 
among Blacks from certain regions in Africa where 
the incidence of this phenotype ranges between 
1 percent and 35 percent16 as compared with an 
incidence of less than 0.001 percent in the White 
population.  However, several studies7–9 have associ-
ated the S–s– phenotype not only with the absence 
of the high-prevalence antigen, U, but also with 
weakened expression of U (the so-called U variant 
[U+var] phenotype).  The S–s–U– phenotype is attribut-
able to the deletion of GYPB, whereas the S–s–U+var 
phenotype is associated with a variant GPB protein 
that often expresses He.4
Our findings were slightly different from previ-
ously reported data when comparing the molecular 
events implicated in the nature of GYPB variant forms 
found in our African Brazilian population.  We report 
that 23.5 percent of African Brazilians phenotyped as 
S–s– presented a variant GYPB and that the +5 nucle-
otide change in intron 5 was the most common (50% 
of samples) mechanism for generating the S–s–U+var 
phenotype, followed by a change at nucleotide 208 
and 230 (25% of samples with a variant GYPB) of 
exon 5 and a heterozygous change at nt208 and nt230 
of exon 5 and +5 of intron 5 (25% of samples with a 
variant GYPB).  However, in this study, we have not 
been able to define the zygosity status of the variant 
GYPB in the donors with S–s–U+var phenotype owing 
to the apparent inability of the AS/RFLP-PCR assay 
to detect the deleted GYPB gene when GYP(P2) or 
GYP(NY) is present as an apparent homozygote.
Fig. 1. AS-PCR for GYPB*S/s.  Electrophoresis profile in agarose gel.  B = water blank control.  CI = internal control.
Fig. 2. Analysis of GYPB exon 5 combination AS/PCR-RFLP assay after 
digestion with EcoRI.  A 10% polyacrylamide gel electrophoresis 
demonstrating the band patterns for interpretation of variant 
forms of GYPB in African Brazilians phenotyped as S–s– or 
S–s+; (M = mutant; W = wild).  Lane 1 is the 100-bp ladder; 
Lane 2 is the uncut PCR product; Lane 3 is digestion pattern of 
an M/M (no EcoRI site present), a GYP(P2); Lanes 4 and 5 are 
digestion patterns of an M/W; Lane 6 is the digestion pattern 
of a W/W, GYPB; Lane 7 is the digestion pattern with the 
allele-specific band GYP(NY); Lane 8 is the uncut PCR product 
of the GYP(NY) showing the allele-specific band.
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All samples from S–s– donors failed to react with 
human polyclonal anti-U.  The absence of reactiv-
ity of our S–s–U+var samples with human polyclonal 
anti-U used in our laboratory raised questions about 
the nature of U on RBCs of normal and variant 
phenotypes.  The molecular basis of U has not been 
identified so far; however, there is evidence to sug-
gest a possible interaction of GPB with Rh-associated 
glycoprotein, RhAG,17,18 which could lead to confor-
mational changes of variant GPB on the RBC surface. 
This is supported by the observation that some anti-
U are compatible with all S–s– RBCs, even S–s–U+var. 
Apparently rare in an electronic literature search, the 
inclusion of African Brazilian blood samples phe-
notyped as S–s+ in this study, to complement and 
confirm the molecular mechanisms responsible for 
the S–s– phenotype, provided the knowledge of a 
high prevalence of GYPB*S in this population (7.4% 
of S–s+ samples), not described in the literature, 
showing heterozygous variant forms of GYP(P2) (73% 
of samples) followed by GYP(NY) (27% of samples). 
The implication of this molecular characteristic for 
blood transfusion practice is unknown and remains 
a challenge for future identification studies of vari-
ant forms; however, it is important that molecular 
methods incorporate the analysis of known GYPB 
variants, especially in a specific population.
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